

DESCRIPTION

Source *E. coli*-derived mouse Galectin-9 protein
Ala2-Thr322
Accession # NP_001152773

N-terminal Sequence Analysis Ala2

Predicted Molecular Mass 36.4 kDa

SPECIFICATIONS

SDS-PAGE 36 kDa, reducing conditions

Activity Measured by the ability of the immobilized protein to support the adhesion of D10.G4.1 mouse helper T cells.
The ED₅₀ for this effect is 0.6-3 µg/mL.

Endotoxin Level <1.0 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in MOPS, NaCl, EDTA, DTT and Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 100 µg/mL in sterile, deionized water.

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

Galectins comprise a family of multifunctional carbohydrate-binding proteins with specificity for N-acetyl-lactosamine-containing glycoproteins. At least 14 mammalian Galectins share structural similarities in their carbohydrate recognition domains (CRD), forming three groups: a prototype group (one CRD), a tandem-repeat group (two CRDs), and a chimeric group (one CRD, unique N-terminus) (1, 2). Full length Galectin-9 is a widely expressed 39 kDa tandem-repeat group Galectin that contains two CRDs connected by a linker region (3). Alternate splicing generates an extended, small intestine-specific isoform with a 31 amino acid insertion in the linker region (3). The standard (or short) isoform of mouse Galectin-9 is orthologous to human galectin-9, which is also known as Ecalectin (4). This isoform shares 70% and 85% aa sequence identity with the corresponding regions of human and rat Galectin-9, respectively. Galectin-9 exhibits a wide range of activities including eosinophil chemoattraction (5-7). This activity is destroyed by thrombin-mediated cleavage within the linker region of the long isoform, although the human Ecalectin isoform is resistant to thrombin (8). Galectin-9 binds to carbohydrate moieties of IgE, thereby preventing immune complex formation, mast cell degranulation, and asthmatic and cutaneous anaphylaxis reactions (9). Independent of its lectin properties, Galectin-9 induces the maturation of dendritic cells which promote Th1 polarization (10). Galectin-9 induces cellular apoptosis in part by direct binding to TIM-3 (11, 12). Its interaction with TIM-3 inhibits Th1 cell and CD8⁺ cytotoxic T cell responses, while also promoting regulatory T cell differentiation and activity (12, 13). Conversely, Galectin-9 is also reported to bind to a non-TIM3 receptor on both Th1 and Th2 cells, promoting both apoptosis and cytokine secretion, suggesting multiple receptors on T helper cells (14). Galectin-9 suppresses tumor cell metastasis by interfering with the associations between hyaluronic acid and CD44 and between VCAM-1 and Integrin $\alpha 4 \beta 1$ (15). Galectin-9, also known as the UAT or urate transporter, can also be expressed as an integral membrane protein in kidney that mediates the cellular efflux of urate (16).

References:

1. Zhu, C. *et al.* (2011) *Curr. Top. Microbiol. Immunol.* **350**:1.
2. Elola, M.T. *et al.* (2007) *Cell. Mol. Life Sci.* **64**:1679.
3. Wada, J. and Y.S. Kanwar (1997) *J. Biol. Chem.* **272**:6078.
4. Matsushita, N. *et al.* (2000) *J. Biol. Chem.* **275**:8355.
5. Matsumoto, R. *et al.* (2002) *J. Immunol.* **168**:1961.
6. Chabot, S. *et al.* (2002) *Glycobiology* **12**:111.
7. Sato, M. *et al.* (2002) *Glycobiology* **12**:191.
8. Nishi, N. *et al.* (2006) *Glycobiology* **16**:15C.
9. Niki, T. *et al.* (2009) *J. Biol. Chem.* **284**:32344.
10. Dai, S.-Y. *et al.* (2005) *J. Immunol.* **175**:2974.
11. Seki, M. *et al.* (2007) *Arthritis Rheum.* **56**:3968.
12. Zhu, C. *et al.* (2005) *Nat. Immunol.* **6**:1245.
13. Sehrawat, S. *et al.* (2010) *PloS Pathogens* **6**:e1000882.
14. Su, E.W. *et al.* (2011) *Glycobiology* **21**:1258.
15. Nobumoto, A. *et al.* (2008) *Glycobiology* **18**:735.
16. Leal-Pinto, E. *et al.* (2002) *Am. J. Physiol. Renal Physiol.* **283**:F150.